Sanofi India Limited is a listed pharmaceutical company focused on manufacturing and marketing prescription medicines in India, with a strategic emphasis on diabetes care (insulin portfolio) and distribution partnerships for cardiovascular, CNS and oral anti‑diabetic categories; it operates manufacturing sites (notably Goa) and sells through independent distributors across domestic and select export markets.

The company completed a pivotal transformation in 2025: refocusing on insulin, launching a partnership model for legacy brands, and reorganizing around digital and AI‑enabled customer engagement, which management cites as the foundation for sustainable, profitable growth even as transitional effects impacted reported revenue and segmental comparability.

Financially the year shows mixed signals: domestic sales were essentially flat (+1% FY), diabetes insulin domestic volumes grew +6% and Q4 diabetes grew +11%, but exports plunged (-40% FY) driven by Ankleshwar divestment and partnership phasing, while operating expenses were cut ~17% year‑on‑year supporting a marginal PBT increase of +1% for FY25.

Sanofi India retains market leadership in basal insulin (Lantus ~31% market share) and is investing to scale Soliqua and Toujeo via private and public sector access, while RWE and clinical work (LANDMARC, Soliqua Phase IV) provide evidence and KOL advocacy to support uptake and formulary inclusion across public programs and tier‑2/3 outreach.

Corporate returns remain shareholder friendly: management proposed a dividend increase of ~5% versus prior year with EPS of INR 142 and a high payout ratio (~87%), reflecting a capital distribution stance supported by operational efficiency despite transitional top‑line headwinds.